Novartis: positive data for Enerzair Breezhaler
(CercleFinance.com) - Novartis announces that, according to a post-hoc analysis, its Enerzair Breezhaler in high doses and once daily, significantly reduces the rates of moderate-to-severe and severe asthma exacerbation rates in some patients, compared to a medium dose.
This analysis, based on data from the pivotal phase III IRIDIUM study and presented at the European Respiratory Society (ERS) International Congress 2020, also shows a safety profile consistent with previous studies, the Swiss Health Group says.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This analysis, based on data from the pivotal phase III IRIDIUM study and presented at the European Respiratory Society (ERS) International Congress 2020, also shows a safety profile consistent with previous studies, the Swiss Health Group says.
Copyright (c) 2020 CercleFinance.com. All rights reserved.